BACKGROUND
Although meningococcal serogroup B (MenB) causes most invasive meningococcal disease (IMD) cases in United States (US) infants, MenB vaccination is not currently approved for this age group. This study sought to better understand US healthcare providers' (HCPs') views regarding IMD and a potential MenB vacci...
O. Herrera-Restrepo, Vasudha Gupta, Sophie Jacobovitz et al.· Expert Review of Vaccines· 0 citations
ABSTRACT In the United States (US), the highest incidence of invasive meningococcal disease (IMD) is among infants aged ≤ 1 year (y). While most IMD cases in US infants are caused by meningococcal serogroup B (MenB), there is no MenB vaccine approved or recommended for US children < 10 y. This study sought to understan...
O. Herrera-Restrepo, Vasudha Gupta, Sophie Jacobovitz et al.· Human Vaccines & Immunothera...· 0 citations
BACKGROUND/OBJECTIVE
Although uncommon, invasive meningococcal disease (IMD) is a serious and life-threatening illness. In the United States (US), incidence is highest among infants aged <1 year, but research characterizing pediatric IMD burden is limited. This study aimed to evaluate health outcomes and economic burde...
O. Herrera-Restrepo, Elizabeth Packnett, Megan K. Richards et al.· PharmacoEconomics - Open· 0 citations
Evidence of high 4CMenB VE against serogroup B-IMD in fully vaccinated infants and children in fully vaccinated infants and children across different geographic regions is provided.
Pavo Marijic, Katarzyna Jamróz-Dolińska, W. Margas et al.· npj Vaccines· 0 citations
While HCPs were receptive to revisions that simplify the vaccine schedule, this was not without concerns; the adolescent vaccination platform is essential to ensure continued protection against IMD; any changes will require clear, evidence-based guidance.
O. Herrera-Restrepo, Laurie Batchelder, T. Pinto et al.· Expert Review of Vaccines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.